Dexamethasone May Prevent Severe AKI in COVID-19 Cases
Inhaled nitric oxide appears to increase the risk for severe acute kidney injury among ICU patients with COVID-19, a French study suggests.
Medications
Aspirin May Lower Cardiovascular Risks in Chronic Kidney Disease Population
Aspirin use among patients with chronic kidney disease was associated with reduced risk for major adverse cardiovascular events.
Optimal Difelikefalin Dose Reported for Pruritus in Hemodialysis
In a previous US phase 2 trial, no clear dose response was observed with difelikefalin.
Dapagliflozin Does Not Improve Kidney Outcomes in Hospitalized COVID-19 Cases
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
Combining Dapagliflozin and Eplerenone Further Reduces Albuminuria in CKD
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Underuse of Diabetic Kidney Disease Therapies Reported
Study findings highlight an “unmet need” for newer therapies.
Infection Risk Varies by Lupus Nephritis Induction Therapy
Adverse effects of induction therapies for lupus nephritis may limit their use.
Colchicine May Lower Risk of CKD Progression
Colchicine, a plant-derived alkaloid, has a broad range of anti-inflammatory effects that interfere with neutrophil function, according to investigators.
AKI Risk in COVID-19 vs Flu Not Disproportionately Higher With RAASi Use
New study is the first to examine the effect of the use of renin-angiotensin-aldosterone system inhibitors on AKI in COVID-19.
RAASi Dose Reduction, Discontinuation in CKD Common After Hyperkalemia
In a study of patients with CKD and/or heart failure on RAASi therapy, the proportion of patients who received dose reductions or had therapy discontinued after new-onset hyperkalemia increased with hyperkalemia severity.
